Hydroxyethyl starch for fluid resuscitation in critically ill patients

Canadian Journal of Anesthesia

Volumn 60, Issue 7, 2013, Pages 709-713

  Bagshaw, Sean M ^a   Chawla, Lakhmir S ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; HYPERTENSIVE AGENT;

ACUTE KIDNEY FAILURE; APACHE; ARTIFICIAL VENTILATION; AUSTRALIA; COST; CRITICALLY ILL PATIENT; ELECTIVE SURGERY; FLUID RESUSCITATION; HUMAN; INJURY; INTENSIVE CARE; LENGTH OF STAY; MORTALITY; MULTICENTER STUDY (TOPIC); NEW ZEALAND; NOTE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; URINE VOLUME;

CRITICAL ILLNESS; FEMALE; FLUID THERAPY; HETASTARCH; HUMANS; MALE;

EID: 84879155689     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-013-9936-4     Document Type: Note

References (25)

1. Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 2010; 14: R185.
2. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6: CD000567.
3. McIntyre LA, Hebert PC, Fergusson D, Cook DJ, Aziz A, Canadian Critical Care Trials Group. A survey of Canadian intensivists' resuscitation practices in early septic shock. Crit Care 2007; 11: R74.
4. Feng X, Liu J, Yu M, Zhu S, Xu J. Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and survival in rats challenged with polymicrobial sepsis. Clin Chim Acta 2007; 376: 60-7.
5. Feng X, Hu Y, Ding J, et al. Early treatment with hydroxyethyl starch 130/0.4 causes greater inhibition of pulmonary capillary leakage and inflammatory response than treatment instituted later in sepsis induced by cecal ligation and puncture in rats. Ann Clin Lab Sci 2007; 37: 49-56.
6. Dieterich HJ, Weissmuller T, Rosenberger P, Eltzschig HK. Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Crit Care Med 2006; 34: 1775-82.
7. Marx G, Pedder S, Smith L, et al. Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kd), but not Ringer's solution maintains plasma volume and systemic oxygenation. Shock 2004; 21: 336-41.
8. Dubin A, Pozo MO, Casabella CA, et al. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. J Crit Care 2010; 25: 659.e1-8.
9. Guidet B, Martinet O, Boulain T, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16: R94.
10. Magder S, Potter BJ, Varennes BD, Doucette S, Fergusson D, Canadian Critical Care Trials Group. Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids. Crit Care Med 2010; 38: 2117-24.
11. Hartog CS, Skupin H, Natanson C, Sun J, Reinhart K. Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses. Intensive Care Med 2012; 38: 1258-71.
12. Gattas DJ, Dan A, Myburgh J, et al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 2012; 114: 159-69.
13. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-6.
14. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-2.
15. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
16. Moskowitz DM, Shander A, Javidroozi M, et al. Postoperative blood loss and transfusion associated with use of Hextend in cardiac surgery patients at a blood conservation center. Transfusion 2008; 48: 768-75.
17. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 2001; 72: 527-33; discussion 534.
18. Rioux JP, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 2009; 37: 1293-8.
19. Huter L, Simon TP, Weinmann L, et al. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009; 13: R23.
20. Sakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216-24.
21. Eisenbach C, Schonfeld AH, Vogt N, et al. Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution. Intensive Care Med 2007; 33: 1637-44.
22. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-11.
23. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-34.
24. Myburgh J, Li Q, Heritier S, Dan A, Glass P, Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Crit Care Resusc 2012; 14: 44-52.
25. Chong PC, Greco EF, Stothart D, et al. Substantial variation of both opinions and practice regarding perioperative fluid resuscitation. Can J Surg 2009; 52: 207-14.